山东大学教师主页窦蕾 Cost-effectiveness analysis of serplulimab plus chemotherapy in the first-line treatment for PD-L1-positive esophageal squamous cell carcinoma in China 中文主页

Cost-effectiveness analysis of serplulimab plus chemotherapy in the first-line treatment for PD-L1-positive esophageal squamous cell carcinoma in China: 发布时间：2023-10-31 | 点击次数：

所属单位：公共卫生学院

发表刊物：Frontiers in Immunology

论文编号：AACF629AB0EF4A22870C33F9DE38ECDF

卷号：14

字数：7

是否译文：否

发表时间：2023-05

上一条： Psychometric properties and comparison of four health utility approaches among myopia patients in China

下一条： Cost-effectiveness analysis of serplulimab plus chemotherapy in the first-line treatment for PD-L1-positive esophageal squamous cell carcinoma in China